drugset
drugset / Trial / NCT01367275

Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF

NCT01367275 ↗

Phase 2 Terminated 8 enrolled M.D. Anderson Cancer Center Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if adding brivanib to irinotecan can help control the disease in patients with colorectal cancer that has spread. The safety of this drug combination will also be studied.

Timeline

Start
2011-08
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Brivanib Small molecule 800 mg Oral
Subject Irinotecan Small molecule 180 mg/m2 Intravenous

Indications

colorectal adenocarcinoma